Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
76,991,404
-
Total 13F shares
-
19,661,979
-
Share change
-
-90,177
-
Total reported value
-
$95,750,005
-
Put/Call ratio
-
70%
-
Price per share
-
$4.87
-
Number of holders
-
52
-
Value change
-
+$477,938
-
Number of buys
-
19
-
Number of sells
-
23
Institutional Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q2 2021
As of 30 Jun 2021,
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) was held by
52 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,661,979 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Carmignac Gestion, ACT Capital Management, LLC, VANGUARD GROUP INC, ACUTA CAPITAL PARTNERS, LLC, TWO SIGMA INVESTMENTS, LP, TWO SIGMA ADVISERS, LP, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
52
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.